No Benefit Seen With Everolimus in Early Breast Cancer

Adding everolimus to adjuvant hormone therapy for early ER+, HER2- breast cancer does not offer any benefit over hormone therapy

Read more

Perjeta

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. PERJETA 180903 Contains the active ingredient pertuzumab

Read more

Monofeme

NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. MONOFEME® Levonorgestrel and Ethinylestradiol Tablets Consumer Medicine

Read more